Portal de investigação
Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Rossignol, P
- Kosiborod, MN
- Brandenburg,
- Cleland, JG
- Hadimeri, H
- Hullin, R
- Makela, S
- Mörtl, D
- Paoletti, E
- Pollock, C
- Vogt, L
- Jadoul, M
- Butler, J
Unidades de investigação
Abstract
Background: Pivotal randomized trials demonstrating efficacy, safety and good tolerance, of two new potassium binders (patiromer and sodium zirconium cyclosilicate) led to their recent approval. A major hurdle to the implementation of these potassium-binders is understanding how to integrate them safely and effectively into the long-term management of cardiovascular and kidney disease patients using renin angiotensin aldosterone system inhibitors (RAASi), the latter being prone to induce hyperkalaemia.Methods: A multidisciplinary academic panel including nephrologists and cardiologists was convened to develop consensus therapeutic algorithm(s) aimed at optimizing the use of the two novel potassium binders (patiromer and sodium zirconium cyclosilicate) in stable adults who require treatment with RAASi and experience(d) hyperkalaemia in a non-emergent setting.Results: Two dedicated pragmatic algorithms are proposed. The lowest intervention threshold (i.e. 5.1 mmol/L or greater) was the one used in the patiromer and sodium zirconium cyclosilicate) pivotal trials, both drugs being indicated to treat hyperkalaemia in a non-emergent setting. Acknowledging the heterogeneity across specialty guidelines in hyperkalaemia definition and thresholds to intervene when facing hyperkalaemia, we have been mindful to use soft language i.e. "it is to consider", not necessarily "to do".Conclusions: Providing the clinical community with pragmatic algorithms may help optimize the management of high-risk patients by avoiding the risks of both hyper and hypokalaemia and of suboptimal RAASi therapy
Dados da publicação
- ISSN/ISSNe:
- 1043-6618, 1096-1186
- Tipo:
- Editorial Material
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Pharmacological Research Academic Press Inc.
Citações Recebidas na Web of Science: 5
Citações Recebidas na Scopus: 8
Documentos
- Não há documentos
Filiações
Keywords
- Potassium binder; Patiromer; Sodium zirconium cyclosilicate; Algorithm; Hyperkalaemia
Financiamento
Proyectos asociados
Registo global de insuficiência cardíaca congestiva.
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Observacional Académico (IC_Congestiva) . 2019
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms (EMPERIAL) - NCT03448406
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Ensaio Clínico Comercial (EMPERIAL) . Boehringer Ingelheim . 2020
Envolva-se com o seu coração: Promoção da adesão terapêutica com um sistema de telemonitorização para pessoas com insuficiência cardíaca crónica. (AdHeart)
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo de Intervenção Académico (AdHeart) . FCT . 2019
Sacubitril/Valsartan in everyday clinical practice: the experience of a heart failure clinic
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Clínico Académico (Sacubitril/Valsartan) . 2020
Avaliação da aorta ascendente em doentes operados a tetralogia de Fallot: implicações no follow-up clínico e imagiológico
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Clínico Académico . 2020
Hyperkalemia as a limiting factor of Neurohormonal Blockade/Modulation in everyday clinical practice
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Clínico Académico . 2020
Reversão da remodelagem ventricular na miocardiopatia dilatada idiopática
Investigador Principal: José Carlos de Magalhães Silva Cardoso
Estudo Clínico Académico . 2019
Citar a publicação
Rossignol P,Silva J,Kosiborod MN,Brandenburg ,Cleland JG,Hadimeri H,Hullin R,Makela S,Mörtl D,Paoletti E,Pollock C,Vogt L,Jadoul M,Butler J. Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease. Pharmacol. Res. 2022. 182106277. IF:9,300. (1).
